NHS-Galleri Trial Misses Primary Endpoint but Shows 26% Reduction in Stage IV Cancer by Third Round
May 31, 2026
The NHS-Galleri trial of the Galleri multi-cancer early detection test did not meet its primary endpoint of reducing combined Stage III-IV cancers. Secondary results showed a 26% reduction in Stage IV diagnoses by the third screening round for 12 deadly cancers. The test increased cancer detection rates four-fold compared to standard screening alone.